The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012
| dc.contributor.author | Kieran, J | |
| dc.contributor.author | Bennett, K | |
| dc.contributor.author | Coghlan, M | |
| dc.contributor.author | Bergin, C | |
| dc.contributor.author | Barry, M | |
| dc.date.accessioned | 2015-06-29T14:41:37Z | en |
| dc.date.available | 2015-06-29T14:41:37Z | en |
| dc.date.issued | 2015-06 | en |
| dc.identifier.citation | Kieran, J. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012. Irish Medical Journal. Vol.108 No.5 2015. | en |
| dc.identifier.uri | http://hdl.handle.net/10147/558638 | en |
| dc.description.abstract | Chronic Hepatitis C (HCV) is estimated to infect 20,000 to 50,000 people in Ireland. National estimates of the number of patients who have been treated for HCV, their demographics and the cost associated with that treatment have not been published. Prescriptions for the treatment of HCV from 2000-2012 were established by interrogating the records of the High-Tech Drug Scheme and the pharmacy records of the Genitourinary Medicine and Infectious Diseases department of St. James Hospital. 2320 patients were initiated on treatment for HCV. Over 27 million was spent on HCV treatment. 25.5 million was spent on anti-viral therapy and 2 million was spent on haematological growth factor support for the management of adverse effects. The budget impact of HCV treatment has been significant in Ireland. New agents for HCV will have a greater budget impact but should require less spend on adverse event management. | |
| dc.language.iso | en | en |
| dc.publisher | Irish Medical Journal | en |
| dc.subject | HEPATITIS C | en |
| dc.subject | CHRONIC DISEASE | en |
| dc.title | The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012 | en |
| dc.type | Article | en |
| dc.identifier.journal | Irish Medical Journal | en |
| dc.description.funding | No funding | en |
| dc.description.province | Leinster | en |
| dc.description.peer-review | peer-review | en |
| refterms.dateFOA | 2018-08-26T20:37:29Z | |
| html.description.abstract | Chronic Hepatitis C (HCV) is estimated to infect 20,000 to 50,000 people in Ireland. National estimates of the number of patients who have been treated for HCV, their demographics and the cost associated with that treatment have not been published. Prescriptions for the treatment of HCV from 2000-2012 were established by interrogating the records of the High-Tech Drug Scheme and the pharmacy records of the Genitourinary Medicine and Infectious Diseases department of St. James Hospital. 2320 patients were initiated on treatment for HCV. Over 27 million was spent on HCV treatment. 25.5 million was spent on anti-viral therapy and 2 million was spent on haematological growth factor support for the management of adverse effects. The budget impact of HCV treatment has been significant in Ireland. New agents for HCV will have a greater budget impact but should require less spend on adverse event management. |
